Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05466448 · ClinicalTrials.gov registry record · Phase 1
An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.
A Phase 1 study, sponsored by Raziel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05466448 is a Phase 1 study that has completed, run by Raziel Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT05466448, a Phase 1 study, has completed, sponsored by Raziel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a Phase 2, open label study that will consist of a screening period, baseline period in which subjects will receive a single treatment session and a follow-up period. The single treatment session will consist of multiple injections of RZL-012 into the submental area under the chin. Blood samples will be collected from all subjects for PK analyses in the first 30 hours after dosing. Subjects will thereafter be monitored for safety and efficacy for at least 84 days.
Interventions
- DRUG RZL-012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-07-29 |
| Est. Completion | 2023-06-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05466448
The ClinicalTrials.gov registry entry for NCT05466448 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Raziel Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RZL-012 is the first listed.
NCT05466448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05466448 about?
NCT05466448 is a clinical study titled "An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.". This is a Phase 2, open label study that will consist of a screening period, baseline period in which subjects will receive a single treatment session and a follow-up period. The single treatment session will consist of multiple injections of RZL-012 into the submental area under the chin. Blood sam...
What is the current status of trial NCT05466448?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-07-29. Estimated completion is 2023-06-15.
What interventions are being tested in trial NCT05466448?
The interventions under investigation include: RZL-012 (DRUG).
Who is sponsoring clinical trial NCT05466448?
This trial is sponsored by Raziel Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.